Central plains Sheikh
Changchun high-tech
Gongda hi-tech
Youhao group
Su Changchai
At the same time, we can pay attention to: Jinbin Development (000897), Hakko (600095), Daan Gene (002030), Rheinland Biology (002 1666) and Tiantan Biology (600 16 1).
The leader of the concept of Zhongyuan Concord stem cells is Saint Concord, whose original name was Saint Wang Chunhua. On February 12 this year, it was officially renamed as "Zhongyuan Xiehe Stem Cell Bioengineering Co., Ltd.", which renamed the concept of stem cells. From the company's public information, we can find that the stem cell industry has become the company's main source of profit. It is a stem cell industrialization base in China and the first member of cord blood bank in Asia. In 2008, corporate profits increased by 270%, and some institutions predict that corporate profits will increase by more than 300% this year. Sheikh Stem Cell Genetic Engineering Co., Ltd., a 57% subsidiary of our company, is an enterprise mainly engaged in cord blood storage business. The development of business has brought huge profit growth to the company. In the future, through the upgrading of stem cell industry, ST Sheikh is expected to gradually extend the stem cell industry chain and eventually expand the company's advantages in the stem cell industry.
Friendship Group established Shanghai Shen You Biotechnology Co., Ltd. together with the "national team" in the field of stem cell research-National Southern Research Center of Human Genome, and participated in the research of "Establishment of heterozygous model of mouse embryonic stem cells with osteoprotegerin gene", and completed the primer synthesis and gene sequencing.
Fuxing Medicine used150,000 yuan to build a biotherapy research center for stem cell transplantation technology research and stem cell bank and biotherapy technology construction.
The main product of Granback Biopharmaceutical Company, which is controlled by Ruimaotong, is human granulocyte colony stimulating factor rhG-CSF, which is a specific drug for treating tumor and cancer, and can be used for peripheral blood stem cell transplantation and bone marrow transplantation.
Sue holds a 25% stake in Tsinghua Xingye Venture Capital Company. Tsinghua Xingye is a well-known venture capital company and a pioneer in the field of biotechnology in China, especially in the fields of stem cells, tissue engineering and gene therapy. And created a series of classic cases in China venture capital market.